Thermeutics, Inc.

Thermeutics, Inc.

by | Aug 4, 2026

Thermeutics is developing Stasis, an implantable system for cytostatic hypothermia that halts glioblastoma by cooling resection margins. Market Opportunity: Glioblastoma is the deadliest brain cancer, with median survival around 15 months. More than 80% of tumors...
NEXT-TFX, Inc.

NEXT-TFX, Inc.

by | Jul 28, 2026

NEXT-TFX, Inc. is developing compaction-resistant reverse osmosis membranes for ultra-high-pressure desalination and brine concentration. Market Opportunity: Seawater desalination, industrial brine concentration, direct lithium extraction, and zero liquid discharge...
My Block Skin, Inc.

My Block Skin, Inc.

by | Jul 10, 2026

My Block Skin develops inclusive sun care technologies that deliver invisible, high-performance UV protection for every skin tone. Market Opportunity: Traditional sunscreens often leave a visible white cast, discouraging daily use among millions of consumers,...
RaizDx

RaizDx

by | Jul 1, 2026

Raiz Diagnostics breaks the bottleneck in expert lymphoma pathology by generating a transcriptomic-derived, clinically actionable diagnosis. Market Opportunity: Diagnosing lymphoma today takes over 3 weeks and $10,000+ per patient, relying on a sequential cascade of...
Paralos Bioscience Inc.

Paralos Bioscience Inc.

by | Mar 4, 2026

Paralos is developing the first-in-class phage-drug conjugate drug delivery platform, with lead asset targeting drug-resistant infections. Market Opportunity: Drug-resistant Gram-negative infections drive sepsis and pneumonia, extending ICU stays and costs; many...